Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis

Read full text Summarise with VIRAT
Authors: Mingjun Rui, Qiran Wei, Yingcheng Wang, Joyce H. S. You
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Recent studies have shown the efficacy of perioperative immunotherapy in improving the event-free survival of patients with advanced resectable melanoma. This study evaluated the cost-effectiveness of different perioperative immunotherapy treatment strategies versus adjuvant immunotherapy treatment strategies from the US payer perspective. Methods Two immunotherapy strategies were each compared with the corresponding standard adjuvant treatment in two Markov models: Model (1) perioperative nivolumab plus ipilimumab versus adjuvant nivolumab for stage III patients; model (2) perioperative pembrolizumab versus adjuvant pembrolizumab for stage IIIB to IVC patients. Primary outcomes included direct costs, life-year gained (LYG), quality-adjusted life-year (QALY), and incremental cost per QALY (ICER). Sensitivity analyses were conducted to evaluate the robustness of the model outcomes. Results In base-case analysis, perioperative nivolumab plus ipilimumab (versus adjuvant nivolumab) gained higher QALY (by 2.73) with cost-saving (by USD109,157) in model (1), and perioperative pembrolizumab (versus adjuvant pembrolizumab) gained higher QALY (by 2.29) with cost-saving (by USD130,157) in model (2). Both perioperative strategies were accepted as cost-effective. One-way sensitivity analyses found the base-case results robust to variation in all model parameters at willingness-to-pay threshold of 100,000 USD/QALY. Probabilistic sensitivity analysis demonstrated that the two perioperative strategies were accepted as cost-effective in 100% of 10,000 simulations. Conclusions Perioperative immunotherapies demonstrated cost-saving compared with adjuvant immunotherapies from the US payer perspective. One-way and probabilistic sensitivity analyses supported the robustness of the cost-effectiveness results. Clinical trial number Not applicable.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Figshare
Publication date
26 February 2026
Language
EN